The true barrier to artificial intelligence (AI) in pathology is not the technology; it’s the business model. Flagship Biosciences believes that the true opportunity for pathology AI lies in personalized medicine with big data. Better characterization of the patient population using rich information data from diagnostics, prognostics and companion diagnostics could make drug development faster and cheaper through smarter patient selection and simplified regulatory pathways.
Read “Intelligent Pharma Partners,” just published in The Pathologist, describing how pharmaceutical companies can partner with pathologists and payers to improve patient care, bring effective therapies to market, and lower costs through AI-assisted pathology.
Is your patient selection optimized with rich information data? Contact Flagship today to discuss how we can help simplify your regulatory pathway.